SYSTEMATIC REVIEW article
Front. Aging Neurosci.
Sec. Alzheimer's Disease and Related Dementias
Volume 17 - 2025 | doi: 10.3389/fnagi.2025.1551939
This article is part of the Research TopicMild cognitive impairment and cognitive agingView all 7 articles
Diagnostic Value of Olfactory Function Testing for Alzheimer’s Disease and Mild Cognitive Impairment: A systematic review and Meta-Analysis
Provisionally accepted
- The First Affiliated Hospital of China Medical University, Shenyang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Alzheimer’s disease (AD) is clinically classified into prodromal (asymptomatic), mild cognitive impairment (MCI) due to AD, and dementia due to AD. This study investigates the diagnostic value of olfactory function testing for AD and MCI.Methods: Systematic searches of PubMed, Web of Science, Cochrane, and EMBASE databases were conducted up to February 1, 2024. Methodological quality was assessed using the revised Quality Assessment of Diagnostic Accuracy Studies. Effect sizes were combined using a random-effects model (DerSimonian-Laird method), and statistical analyses were conducted using STATA 15.1 and Meta-Disc 1.4 software.Results: Twenty-five studies with 13,611 participants were included. For diagnosing AD, combined sensitivity (SE) was 0.79 (95% CI: 0.71-0.85), specificity (SP) was 0.78 (95% CI: 0.69-0.84), and AUC was 0.85 (95% CI: 0.82-0.88). For MCI, SE was 0.67 (95% CI: 0.54-0.78), SP was 0.79 (95% CI: 0.71-0.86), and AUC was 0.81 (95% CI: 0.77-0.84). Combined SE and SP for diagnosing AD and MCI were 0.58 (95% CI: 0.46-0.68) and 0.88 (95% CI: 0.78-0.93), with an AUC of 0.78 (95% CI: 0.74-0.82). SE and SP for AD or MCI were 0.83 (95% CI: 0.36-0.98) and 0.94 (95% CI: 0.82-0.98), with an AUC of 0.96 (95% CI: 0.94-0.98).Conclusions: This systematic review and meta-analysis reveal that olfactory function testing, as a simple, non-invasive, and cost-effective assessment method, demonstrates high diagnostic efficacy in the early identification of AD and MCI, showing promising clinical application.
Keywords: Olfactory disorder, Olfactory Function Testing, Alzheimer's disease, Mild Cognitive Impairment, diagnosis
Received: 26 Dec 2024; Accepted: 30 Apr 2025.
Copyright: © 2025 Liu, Cao and Wei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yunpeng Cao, The First Affiliated Hospital of China Medical University, Shenyang, China
Hongquan Wei, The First Affiliated Hospital of China Medical University, Shenyang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.